
## Juraj Bodo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4783421/publications.pdf Version: 2024-02-01



| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Immune Escape Mechanisms in Intravascular Large B-Cell Lymphoma: A Molecular Cytogenetic and<br>Immunohistochemical Study. American Journal of Clinical Pathology, 2022, 157, 578-585.   | 0.7 | 5         |
| 2  | Analytical Accuracy of RET Fusion Detection by Break-Apart Fluorescence In Situ Hybridization.<br>Archives of Pathology and Laboratory Medicine, 2022, 146, 351-359.   | 2.5 | 5         |
| 3  | Proteomic characterisations of ulcerative colitis endoscopic biopsies associate with clinically relevant histological measurements of disease severity. Journal of Clinical Pathology, 2022, 75, 636-642.  | 2.0 | 2         |
| 4  | Decreased BIM expression in BCL2-negative follicular lymphoma: a potential mechanism for resistance to apoptosis. Human Pathology, 2021, 107, 1-8.   | 2.0 | 2         |
| 5  | Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies. Cell Death and Disease, 2021, 12, 1061.   | 6.3 | 8         |
| 6  | Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. Cell Death and Disease, 2020, 11, 941.   | 6.3 | 115       |
| 7  | Inhibition of cyclinâ€dependent kinase 9 synergistically enhances venetoclax activity in mantle cell<br>lymphoma. EJHaem, 2020, 1, 161-169.  | 1.0 | 2         |
| 8  | Immunohistochemical Expression of Lymphoid Enhancer Binding Factor 1 in CD5-Positive Marginal<br>Zone, Lymphoplasmacytic, and Follicular Lymphomas. American Journal of Clinical Pathology, 2020, 153,<br>646-655.   | 0.7 | 9         |
| 9  | Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in<br>Multiple Myeloma. Cancer Research, 2020, 80, 2031-2044.  | 0.9 | 36        |
| 10 | SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target. British Journal of Haematology, 2019, 185, 145-147.   | 2.5 | 9         |
| 11 | Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies. Cell Death and Disease, 2019, 10, 924.  | 6.3 | 51        |
| 12 | Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting<br>Therapeutic Antibody, Elotuzumab. Blood, 2019, 134, 1515-1515.  | 1.4 | 0         |
| 13 | Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a<br>Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations. Blood, 2019, 134, 1572-1572.  | 1.4 | 0         |
| 14 | CAL2 Immunohistochemical Staining Accurately Identifies <i>CALR</i> Mutations in Myeloproliferative Neoplasms. American Journal of Clinical Pathology, 2016, 146, 431-438.   | 0.7 | 17        |
| 15 | Acquired resistance to venetoclax (ABT-199) in <i>t(14;18)</i> positive lymphoma cells. Oncotarget, 2016,<br>7, 70000-70010.   | 1.8 | 59        |
| 16 | CCMCL1: a new model of aggressive mantle cell lymphoma. Blood, 2015, 125, 2730-2732.   | 1.4 | 17        |
| 17 | Combination of ibrutinib with <scp>ABT</scp> â€199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of <scp>BTK</scp> , <scp> AKT</scp> and <scp>BCL</scp> 2 pathways. British Journal of Haematology, 2015, 168, 765-768.  | 2.5 | 75        |
| 18 | The phosphatidylinositol 3â€kinases ( <scp>PI</scp> 3 <scp>K</scp> ) inhibitor <scp>GS</scp> â€1101<br>synergistically potentiates histone deacetylase inhibitorâ€induced proliferation inhibition and<br>apoptosis through the inactivation of <scp>PI</scp> 3 <scp>K</scp> and extracellular signalâ€regulated<br>kinase pathways. British Journal of Haematology, 2013, 163, 72-80. | 2.5 | 28        |

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells. Apoptosis: an International Journal on Programmed Cell Death, 2011, 16, 914-923. | 4.9 | 13        |